Analysts expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to announce sales of $450,000.00 for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Syros Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $400,000.00 and the highest estimate coming in at $560,000.00. Syros Pharmaceuticals reported sales of $890,000.00 during the same quarter last year, which would suggest a negative year-over-year growth rate of 49.4%. The business is expected to report its next earnings report on Thursday, March 5th.
On average, analysts expect that Syros Pharmaceuticals will report full year sales of $1.93 million for the current financial year, with estimates ranging from $1.87 million to $2.03 million. For the next year, analysts expect that the company will report sales of $1.96 million, with estimates ranging from $1.60 million to $2.23 million. Zacks’ sales averages are an average based on a survey of analysts that follow Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.01. The business had revenue of $0.56 million for the quarter, compared to analyst estimates of $0.43 million. Syros Pharmaceuticals had a negative net margin of 3,115.38% and a negative return on equity of 84.49%.
In other Syros Pharmaceuticals news, insider Jeremy P. Springhorn purchased 9,879 shares of the stock in a transaction on Monday, November 11th. The shares were purchased at an average cost of $4.99 per share, for a total transaction of $49,296.21. Following the purchase, the insider now owns 24,879 shares of the company’s stock, valued at $124,146.21. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 14.80% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. grew its stake in Syros Pharmaceuticals by 1.7% in the second quarter. JPMorgan Chase & Co. now owns 407,843 shares of the company’s stock valued at $3,242,000 after purchasing an additional 6,771 shares in the last quarter. Samsara BioCapital LLC grew its stake in shares of Syros Pharmaceuticals by 62.9% in the second quarter. Samsara BioCapital LLC now owns 1,726,603 shares of the company’s stock valued at $15,228,000 after buying an additional 666,665 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in Syros Pharmaceuticals by 191.6% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 4,633,773 shares of the company’s stock worth $48,099,000 after buying an additional 3,044,728 shares during the last quarter. BlackRock Inc. increased its holdings in Syros Pharmaceuticals by 32.7% during the second quarter. BlackRock Inc. now owns 2,667,156 shares of the company’s stock worth $24,698,000 after buying an additional 656,735 shares during the last quarter. Finally, ARK Investment Management LLC increased its holdings in Syros Pharmaceuticals by 26.7% during the second quarter. ARK Investment Management LLC now owns 3,791,756 shares of the company’s stock worth $35,112,000 after buying an additional 799,056 shares during the last quarter.
SYRS stock traded down $0.04 during trading hours on Tuesday, reaching $4.60. 190,081 shares of the stock were exchanged, compared to its average volume of 235,109. The firm’s 50-day moving average is $5.23 and its 200-day moving average is $7.73. Syros Pharmaceuticals has a 12 month low of $4.53 and a 12 month high of $11.93. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.92 and a quick ratio of 4.92.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Read More: Balanced Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.